Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PSDV's Cash to Debt is ranked higher than
99% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. PSDV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PSDV' s 10-Year Cash to Debt Range
Min: 0.47  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.78
PSDV's Equity to Asset is ranked higher than
74% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PSDV: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
PSDV' s 10-Year Equity to Asset Range
Min: 0.47  Med: 0.71 Max: 0.91
Current: 0.78
0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
98% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 933.44 vs. PSDV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PSDV' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 7
Z-Score: 0.63
M-Score: 1.88
WACC vs ROIC
6.53%
469.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 28.77
PSDV's Operating margin (%) is ranked higher than
92% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. PSDV: 28.77 )
Ranked among companies with meaningful Operating margin (%) only.
PSDV' s 10-Year Operating margin (%) Range
Min: -4862.16  Med: -1152.63 Max: 39.44
Current: 28.77
-4862.16
39.44
Net-margin (%) 28.46
PSDV's Net-margin (%) is ranked higher than
92% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. PSDV: 28.46 )
Ranked among companies with meaningful Net-margin (%) only.
PSDV' s 10-Year Net-margin (%) Range
Min: -4638.7  Med: -704.34 Max: 37.97
Current: 28.46
-4638.7
37.97
ROE (%) 29.13
PSDV's ROE (%) is ranked higher than
90% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. PSDV: 29.13 )
Ranked among companies with meaningful ROE (%) only.
PSDV' s 10-Year ROE (%) Range
Min: -133.19  Med: -60.18 Max: 30.94
Current: 29.13
-133.19
30.94
ROA (%) 22.36
PSDV's ROA (%) is ranked higher than
93% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. PSDV: 22.36 )
Ranked among companies with meaningful ROA (%) only.
PSDV' s 10-Year ROA (%) Range
Min: -95.61  Med: -45.34 Max: 21.85
Current: 22.36
-95.61
21.85
ROC (Joel Greenblatt) (%) 149.43
PSDV's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. PSDV: 149.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PSDV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15359.59  Med: -3663.46 Max: 16680.73
Current: 149.43
-15359.59
16680.73
Revenue Growth (3Y)(%) -19.60
PSDV's Revenue Growth (3Y)(%) is ranked lower than
89% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PSDV: -19.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PSDV' s 10-Year Revenue Growth (3Y)(%) Range
Min: -58.1  Med: 13.10 Max: 85
Current: -19.6
-58.1
85
EBITDA Growth (3Y)(%) 10.60
PSDV's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. PSDV: 10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PSDV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -22.60 Max: 86.4
Current: 10.6
0
86.4
EPS Growth (3Y)(%) 3.70
PSDV's EPS Growth (3Y)(%) is ranked lower than
51% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. PSDV: 3.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PSDV' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.5  Med: 41.45 Max: 108.1
Current: 3.7
-71.5
108.1
» PSDV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PSDV Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

PSDV Guru Trades in Q3 2014

Jim Simons 125,100 sh (New)
» More
Q4 2014

PSDV Guru Trades in Q4 2014

Jim Simons 68,400 sh (-45.32%)
» More
Q1 2015

PSDV Guru Trades in Q1 2015

Jim Simons 194,800 sh (+184.80%)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.91
PSDV's P/E(ttm) is ranked higher than
78% of the 469 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.80 vs. PSDV: 16.91 )
Ranked among companies with meaningful P/E(ttm) only.
PSDV' s 10-Year P/E(ttm) Range
Min: 8.22  Med: 17.10 Max: 37.86
Current: 16.91
8.22
37.86
PE(NRI) 17.30
PSDV's PE(NRI) is ranked higher than
77% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.50 vs. PSDV: 17.30 )
Ranked among companies with meaningful PE(NRI) only.
PSDV' s 10-Year PE(NRI) Range
Min: 8.18  Med: 17.11 Max: 37.41
Current: 17.3
8.18
37.41
P/B 3.98
PSDV's P/B is ranked lower than
54% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. PSDV: 3.98 )
Ranked among companies with meaningful P/B only.
PSDV' s 10-Year P/B Range
Min: 0.01  Med: 2.44 Max: 11.73
Current: 3.98
0.01
11.73
P/S 4.32
PSDV's P/S is ranked lower than
58% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. PSDV: 4.32 )
Ranked among companies with meaningful P/S only.
PSDV' s 10-Year P/S Range
Min: 0.38  Med: 10.24 Max: 1600
Current: 4.32
0.38
1600
PFCF 10.81
PSDV's PFCF is ranked higher than
90% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. PSDV: 10.81 )
Ranked among companies with meaningful PFCF only.
PSDV' s 10-Year PFCF Range
Min: 9.21  Med: 11.46 Max: 105
Current: 10.81
9.21
105
POCF 10.49
PSDV's POCF is ranked higher than
88% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. PSDV: 10.49 )
Ranked among companies with meaningful POCF only.
PSDV' s 10-Year POCF Range
Min: 7.11  Med: 10.69 Max: 35
Current: 10.49
7.11
35
EV-to-EBIT 10.57
PSDV's EV-to-EBIT is ranked higher than
83% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. PSDV: 10.57 )
Ranked among companies with meaningful EV-to-EBIT only.
PSDV' s 10-Year EV-to-EBIT Range
Min: -430.1  Med: -2.95 Max: 37.5
Current: 10.57
-430.1
37.5
Current Ratio 14.91
PSDV's Current Ratio is ranked higher than
93% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. PSDV: 14.91 )
Ranked among companies with meaningful Current Ratio only.
PSDV' s 10-Year Current Ratio Range
Min: 0.26  Med: 5.46 Max: 17.6
Current: 14.91
0.26
17.6
Quick Ratio 14.91
PSDV's Quick Ratio is ranked higher than
94% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. PSDV: 14.91 )
Ranked among companies with meaningful Quick Ratio only.
PSDV' s 10-Year Quick Ratio Range
Min: 0.26  Med: 5.46 Max: 17.6
Current: 14.91
0.26
17.6
Days Sales Outstanding 5.93
PSDV's Days Sales Outstanding is ranked higher than
96% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. PSDV: 5.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
PSDV' s 10-Year Days Sales Outstanding Range
Min: 17.59  Med: 127.86 Max: 493.85
Current: 5.93
17.59
493.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.69
PSDV's Price/Net Cash is ranked higher than
76% of the 184 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.71 vs. PSDV: 4.69 )
Ranked among companies with meaningful Price/Net Cash only.
PSDV' s 10-Year Price/Net Cash Range
Min: 2.02  Med: 8.76 Max: 246
Current: 4.69
2.02
246
Price/Net Current Asset Value 4.42
PSDV's Price/Net Current Asset Value is ranked higher than
73% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. PSDV: 4.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PSDV' s 10-Year Price/Net Current Asset Value Range
Min: 1.82  Med: 7.37 Max: 316
Current: 4.42
1.82
316
Price/Tangible Book 4.32
PSDV's Price/Tangible Book is ranked lower than
51% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. PSDV: 4.32 )
Ranked among companies with meaningful Price/Tangible Book only.
PSDV' s 10-Year Price/Tangible Book Range
Min: 1.76  Med: 6.94 Max: 105.33
Current: 4.32
1.76
105.33
Price/Median PS Value 0.43
PSDV's Price/Median PS Value is ranked higher than
95% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. PSDV: 0.43 )
Ranked among companies with meaningful Price/Median PS Value only.
PSDV' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 1.05 Max: 129.52
Current: 0.43
0.07
129.52
Price/Graham Number 1.69
PSDV's Price/Graham Number is ranked higher than
68% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.75 vs. PSDV: 1.69 )
Ranked among companies with meaningful Price/Graham Number only.
PSDV' s 10-Year Price/Graham Number Range
Min: 1.44  Med: 1.76 Max: 3.87
Current: 1.69
1.44
3.87
Earnings Yield (Greenblatt) (%) 9.61
PSDV's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. PSDV: 9.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PSDV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.7  Med: 8.90 Max: 18.4
Current: 9.61
2.7
18.4

Analyst Estimate

Jun15
EPS($) -0.29
EPS without NRI($) -0.29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PVA.Australia, PV3.Germany, PSIZF.USA, PV3A.Germany,
pSivida Corp was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials, use different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.0 million people have diabetes in the seven EU countries where ILUVIEN has received or been recommended for marketing authorization, of which Alimera has estimated that approximately 1.1 million people suffer from vision loss associated with DME. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. It faces substantial competition for its products and product candidates. Its competitors and potential competitors are larger, better established and more experienced and have substantially more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.
» More Articles for PSDV

Headlines

Articles On GuruFocus.com
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 
pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2008; Iluvien™ NDA filing Feb 11 2009 

More From Other Websites
pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015 Jun 24 2015
pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015 Jun 24 2015
Edited Transcript of PSDV earnings conference call or presentation 8-May-15 12:30pm GMT Jun 17 2015
pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis May 19 2015
pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis May 19 2015
PSIVIDA CORP. Financials May 15 2015
pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company May 12 2015
pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company May 12 2015
pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company May 12 2015
10-Q for pSivida Corp. May 10 2015
pSivida Corp Earnings Call scheduled for 8:30 am ET today May 08 2015
pSivida Corp. Reports Third Quarter FY 2015 Results May 08 2015
PSivida reports 3Q loss May 08 2015
PSivida reports 3Q loss May 08 2015
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2015
pSivida Corp. Reports Third Quarter FY 2015 Results May 08 2015
Q3 2015 pSivida Corp Earnings Release - Before Market Open May 08 2015
pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference... May 01 2015
pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference... May 01 2015
pSivida Corp. Reports ILUVIEN® for DME Approved in Poland Apr 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK